riluzole

Ligand id: 2326

Name: riluzole

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 2
Hydrogen bond donors 1
Rotatable bonds 2
Topological polar surface area 76.38
Molecular weight 234.01
XLogP 2.42
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

References
1. Ahn HS, Kim SE, Jang HJ, Kim MJ, Rhie DJ, Yoon SH, Jo YH, Kim MS, Sung KW, Hahn SJ. (2006)
Interaction of riluzole with the closed inactivated state of Kv4.3 channels.
J. Pharmacol. Exp. Ther.319 (1): 323-31. [PMID:16815868]
2. Arun T, Tomassini V, Sbardella E, de Ruiter MB, Matthews L, Leite MI, Gelineau-Morel R, Cavey A, Vergo S, Craner M et al.. (2013)
Targeting ASIC1 in primary progressive multiple sclerosis: evidence of neuroprotection with amiloride.
Brain136 (Pt 1): 106-15. [PMID:23365093]
3. Duprat F, Lesage F, Patel AJ, Fink M, Romey G, Lazdunski M. (2000)
The neuroprotective agent riluzole activates the two P domain K(+) channels TREK-1 and TRAAK.
Mol. Pharmacol.57 (5): 906-12. [PMID:10779373]
4. Grunnet M, Jespersen T, Angelo K, Frøkjaer-Jensen C, Klaerke DA, Olesen SP, Jensen BS. (2001)
Pharmacological modulation of SK3 channels.
Neuropharmacology40 (7): 879-87. [PMID:11378158]
5. Killestein J, Kalkers NF, Polman CH. (2005)
Glutamate inhibition in MS: the neuroprotective properties of riluzole.
J. Neurol. Sci.233 (1-2): 113-5. [PMID:15949499]
6. Mostert J, Heersema T, Mahajan M, Van Der Grond J, Van Buchem MA, De Keyser J. (2013)
The effect of fluoxetine on progression in progressive multiple sclerosis: a double-blind, randomized, placebo-controlled trial.
ISRN Neurol2013: 370943. [PMID:23984093]
7. Mostert JP, Koch MW, Heerings M, Heersema DJ, De Keyser J. (2008)
Therapeutic potential of fluoxetine in neurological disorders.
CNS Neurosci Ther14 (2): 153-64. [PMID:18482027]
8. Sankaranarayanan A, Raman G, Busch C, Schultz T, Zimin PI, Hoyer J, Köhler R, Wulff H. (2009)
Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure.
Mol. Pharmacol.75 (2): 281-95. [PMID:18955585]